Clinical Trials in the Wake of Vioxx

This publication has 38 references indexed in Scilit:

• Mortality Reduction by Implantable Cardioverter-Defibrillators in High-Risk Patients With Heart Failure, Ischemic Heart Disease, and New-Onset Ventricular Arrhythmia
  Journal of the American College of Cardiology, 2005
• Influence of clinical trial enrollment on the quality of care and outcomes for patients with non–ST-segment elevation acute coronary syndromes
  American Heart Journal, 2005
• Vioxx, the implosion of Merck, and aftershocks at the FDA
  The Lancet, 2004
• Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
  The Lancet, 2004
• Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry
  American Heart Journal, 2003
• Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure
  Circulation, 2002
• Long QT syndromes and torsade de pointes
  The Lancet, 1999
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
  The Lancet, 1999
• Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction
  New England Journal of Medicine, 1989
• The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
  New England Journal of Medicine, 1987